Could this pill tame rare immune tumors?
NCT ID NCT06411821
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a drug called ulixertinib for people with histiocytic neoplasms, a rare group of disorders where immune cells form tumors. The drug is taken as a pill twice daily. Researchers want to see if it can shrink tumors and control the disease. The trial will enroll 38 adults and is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ulixertinib (BVD-523), an oral drug
- What this could lead to
- If successful, this could provide a new treatment option for people with histiocytic neoplasms, potentially shrinking tumors and controlling the disease.
- What could go wrong
- This is a small Phase 2 trial with only 38 participants, so results may not apply to everyone. The drug may cause side effects or not work as hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HISTIOCYTIC NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic (Data Collection Only)
RECRUITINGRochester, Minnesota, 55905, United States
-
Memorial Sloan Kettering Basking Ridge (Consent Only)
RECRUITINGBasking Ridge, New Jersey, 07920, United States
-
Memorial Sloan Kettering Bergen (Consent Only)
RECRUITINGMontvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
RECRUITINGNew York, New York, 10065, United States
-
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
RECRUITINGMiddletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Nassau (Consent Only)
RECRUITINGUniondale, New York, 11553, United States
-
Memorial Sloan Kettering Suffolk-Commack (Consent Only)
RECRUITINGCommack, New York, 11725, United States
-
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
RECRUITINGHarrison, New York, 10604, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.